All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

AM-Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

AM-Pharma Increases Funding To €163m For Phase-Iii Trial Of Recap In Sa-Aki

Contact the Supplier

Lead Product(s): Recombinant Alkaline Phosphatase

Therapeutic Area: Nephrology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Cowen Healthcare Investments

Deal Size: $52.0 million Upfront Cash: Undisclosed

Deal Type: Funding March 31, 2020

Details:

New capital to be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI).